Apr 15 |
All You Need to Know About Werewolf Therapeutics (HOWL) Rating Upgrade to Buy
|
Apr 5 |
Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting
|
Apr 4 |
Werewolf Therapeutics: In The Hunt For Success In The Cytokine Space
|
Apr 4 |
Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting
|
Mar 12 |
How Much Upside is Left in Werewolf Therapeutics, Inc. (HOWL)? Wall Street Analysts Think 92.37%
|
Mar 9 |
Werewolf Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
|
Mar 7 |
Werewolf Therapeutics GAAP EPS of -$0.33, revenue of $1.5M
|
Mar 7 |
Werewolf Therapeutics, Inc. (HOWL) Reports Q4 Loss, Lags Revenue Estimates
|
Mar 7 |
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
|
Mar 6 |
Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference
|